555 Recruiting Trials

Clinical Trials
for Cancer in Michigan

555 clinical trials for Cancer are currently recruiting participants at study sites in Michigan. Study-related care is provided at no cost.

555
Recruiting trials
422
Study sites
71
Cities
344
Industry-sponsored
223
Phase 2
168
Phase 3

Cancer clinical trials in Michigan: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Michigan, recruiting cancer studies are concentrated in Detroit, Ann Arbor, Grand Rapids and Lansing, with sites in 67 other cities. 344 of the 555 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 555 recruiting Cancer trials in Michigan

Pan Tumor Rollover Study
PHASE2 Huntsville, Alabama +4 sites NCT03899155
This trial is looking for patients with cancer who have had a good response to previous treatments. Participants will continue receiving nivolumab alone or in combination with other cancer therapies to study long-term safety.
Recruiting
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
NA Detroit, Michigan NCT06908629
This trial is looking for cancer survivors who live in Metro Detroit. Participants will fill out a survey about their social needs, which may help them access resources and support.
Recruiting
Connect for Cancer Prevention Study (Connect)
N/A Detroit, Michigan +4 sites NCT04609072
This trial is looking for adults between 30 and 70 years old who have never had cancer. Participants will help researchers learn about cancer risk by answering online health surveys and donating blood, urine, and saliva samples.
Recruiting
Prospective Study to Assess a Diagnostic Aid for Cancer
N/A Coronado, California +4 sites NCT07046260
This trial is looking for people aged 45 and older who have symptoms that might suggest cancer. Participants will take a blood test and may also have additional standard tests to see if cancer is present.
Recruiting
Childhood Cancer Survivor Study
N/A Birmingham, Alabama +4 sites NCT01120353
This trial is looking for childhood cancer survivors who were diagnosed before age 21 and survived for at least five years. Participants will be followed to understand the long-term effects of their cancer treatments.
Recruiting
The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Care
N/A Flint, Michigan +1 sites NCT07461493
This trial is looking for adults aged 35 and older to help research cancer care and barriers to screening in underrepresented communities. Participants will attend annual clinic visits, answer health questionnaires, allow access to their medical records, and provide some samples for research.
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
PHASE3 Scottsdale, Arizona +4 sites NCT05696626
This trial is looking for men and women with advanced breast cancer that expresses estrogen receptors and has a specific genetic mutation. Participants will receive either lasofoxifene or fulvestrant along with another drug called abemaciclib.
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
PHASE3 Gilbert, Arizona +4 sites NCT05894239
This trial is looking for people with advanced breast cancer that is HER2-positive and has a specific mutation. Participants will take a combination of medicines after their initial treatment.
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
PHASE3 Orange, California +4 sites NCT06136624
This trial is looking for men with metastatic prostate cancer that is resistant to hormonal therapy. Participants will receive either Opevesostat or another approved treatment to see which is more effective in improving survival.
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
PHASE2 Anchorage, Alaska +4 sites NCT07063745
This trial is looking for people with advanced lung cancer who have a specific genetic change. Participants will receive either a combination of Navlimetostat, pembrolizumab, and chemotherapy or a placebo with the same treatments.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
PHASE3 Fairbanks, Alaska +4 sites NCT06758401
This trial is looking for people with advanced lung cancer who have high levels of a specific protein called PD-L1. Participants will receive a combination treatment of two medications or just one and will be monitored regularly at a clinic.
Recruiting
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
PHASE3 Detroit, Michigan +4 sites NCT06915025
This trial is looking for women aged 18 and older who have been diagnosed with advanced ovarian, fallopian tube, or peritoneal cancer. Participants will receive a new treatment called IMNN-001 along with standard chemotherapy to see how effective and safe it is.
Recruiting
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
PHASE3 Huntsville, Alabama +4 sites NCT07541079
This trial is looking for women with early breast cancer who have had problems with a previous hormonal treatment. If you join, you will switch to taking giredestrant as part of your cancer care.
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
PHASE3 Chandler, Arizona +4 sites NCT07291037
This trial is looking for patients with advanced lung cancer that tests positive for a specific protein. Participants will receive either datopotamab deruxtecan or docetaxel as treatment.
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
PHASE3 Newport Beach, California +4 sites NCT07419295
This trial is looking for people with bladder cancer that has spread or got worse after previous treatments. Participants will receive a new treatment called sacituzumab tirumotecan and be compared to those receiving standard chemotherapy options.
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
PHASE3 Mobile, Alabama +4 sites NCT07472517
This trial is looking for adults with advanced small cell lung cancer. Participants will receive either a study medicine called obrixtamig along with standard treatment or just the standard treatment alone. The goal is to see if the study medicine helps improve survival.
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
PHASE3 Mobile, Alabama +4 sites NCT06561386
This trial is looking for people with advanced non-small cell lung cancer who have not received prior treatment. Participants will compare two different groups of treatment involving chemotherapy and specific medications.
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
PHASE3 Farmington Hills, Michigan +4 sites NCT07541170
This trial is looking for people with non-small cell lung cancer that has been surgically removed. Participants will be given either a new treatment called divarasib or an immunotherapy chosen by their doctor.
Recruiting
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
PHASE3 Anchorage, Alaska +4 sites NCT07018869
This trial is looking for people who have recently been diagnosed with stage II or III colorectal cancer and want to improve their follow-up care. Participants will use an educational website with a supportive person in their life to learn about managing their health after cancer treatment.
Recruiting

Where the Cancer studies are in Michigan

  • Trinity Health Saint Mary Mercy Livonia Hospital, Livonia61 trials
  • Karmanos Cancer Institute, Detroit60 trials
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton57 trials
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea57 trials
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton56 trials
  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti56 trials

Counts are recruiting studies listing at least one site in Michigan, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Michigan: common questions

How many Cancer clinical trials are recruiting in Michigan?
TrialFinder currently lists 555 recruiting Cancer clinical trials with study sites in Michigan. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Michigan?
Study sites for the Cancer trials listed on this page include Detroit, Flint, Farmington Hills. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Michigan?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Michigan also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Michigan?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Michigan.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →